Clinical trials have shown that abiraterone treatment leads to significant declines in prostate-specific antigen (PSA) levels, objective radiologic responses, and a reduction in circulating tumor cells, indicating that androgen signaling continues to sustain many cases of CRPC. The gene discussed is KLK3; the disease is neoplasm.